IL2 and melanoma: In addition, a randomized phase II study evaluating sequential therapy with aflibercept and high-dose IL-2 versus high-dose IL-2 alone for inoperable stage III or IV melanoma, demonstrated superior antitumor efficacy with combination therapy compared to monotherapy [147].